Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned

MT Drake, BL Clarke, MJ Oursler, S Khosla - Endocrine reviews, 2017 - academic.oup.com
Cathepsin K is a cysteine protease member of the cathepsin lysosomal protease family.
Although cathepsin K is highly expressed in osteoclasts, lower levels of cathepsin K are also …

Novel therapies for osteoporosis

P Makras, S Delaroudis, AD Anastasilakis - Metabolism, 2015 - Elsevier
Since the identification of osteoporosis as a major health issue in aging populations and the
subsequent development of the first treatment modalities for its management, considerable …

Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences

D Brömme, P Panwar, S Turan - Expert opinion on drug discovery, 2016 - Taylor & Francis
Introduction: The osteoporosis market reached a value of more than $11 billion in 2015.
Current treatments remain mostly antiresorptive and comprise of bisphosphonates, the anti …

Pharmacological inhibition of cathepsin K: a promising novel approach for postmenopausal osteoporosis therapy

K Mukherjee, N Chattopadhyay - Biochemical pharmacology, 2016 - Elsevier
Osteoporosis is a metabolic bone disease that is characterized by heightened state of bone
resorption accompanied by diminished bone formation, leading to a reduction of bone …

Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss

A Fontalis, E Kenanidis, RA Kotronias… - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: Pharmacological options to address the imbalance between bone resorption
and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique …

From disease to treatment: from rare skeletal disorders to treatments for osteoporosis

NM Appelman-Dijkstra, SE Papapoulos - Endocrine, 2016 - Springer
During the past 15 years there has been an expansion of our knowledge of the cellular and
molecular mechanisms regulating bone remodeling that identified new signaling pathways …

Future directions for new medical entities in osteoporosis

S Ferrari - Best Practice & Research Clinical Endocrinology & …, 2014 - Elsevier
Odanacatib, a selective cathepsin K inhibitor, decreases bone resorption, whereas
osteoclast number increases and bone formation is maintained, perhaps even increased on …

Novel approaches to the treatment of osteoporosis

NM Appelman-Dijkstra, SE Papapoulos - Best Practice & Research Clinical …, 2014 - Elsevier
Despite the availability of efficacious treatments for fracture reduction in patients with
osteoporosis, there are still unmet needs requiring a broader range of therapeutics. In …

Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys

LT Duong, M Pickarski, T Cusick, CM Chen, Y Zhuo… - Bone, 2016 - Elsevier
The objectives here were to evaluate the effects of odanacatib (ODN) at doses exceeding
the clinical exposure on biomechanical properties of lumbar vertebrae (LV), hip and central …

Beyond resorption: osteoclasts as drivers of bone formation

Q Xiang, L Li, W Ji, D Gawlitta, XF Walboomers… - Cell Regeneration, 2024 - Springer
Emerging evidence illustrates that osteoclasts (OCs) play diverse roles beyond bone
resorption, contributing significantly to bone formation and regeneration. Despite this, OCs …